

Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan

STOCKHOLM, Sweden, 20th August 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that the clinical trial material for the company's upcoming clinical Phase III study with the drug candidate AKP02G2 is ready and has been shipped to our CRO. It marks a critical milestone in the project plan and creates the conditions for the start of studies according to plan. The main aim of the study is to compare the therapeutic efficacy of AKP02G2 against mild to moderate psoriasis with a market-leading product.

Production of clinical trial material is an extensive exercise and a prerequisite for being able to carry out the clinical study. The process must ensure that the material is of the highest quality for use on humans.

"I note that our partner Oy Medfiles has done a first-class job in producing clinical trial material according to schedule. The purchase and completion of materials including their transportation is a critical process and we are very happy to have achieved this milestone in the project together," says Ola Holmlund, CEO of Lipidor.

Preparations for the study itself are also on track and, among other things, approval has already been obtained from the ethics committee for around half of the clinics.

The Phase III study will include 294 patients and is being conducted by Cliantha Research, a reputable CRO (Clinical Research Organisation) with extensive experience in dermatological research. The next major milestone is to initiate the work at the clinics and enroll the first patient to the study. We estimate that this will happen towards the end of next month.

Publication

The information was provided for publication by Lipidor's CEO on 20th August 2024 at 1.50pm (CEST).

For more information, please contact:

Ola Holmlund, CEO, Lipidor AB (publ)
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

About Lipidor AB

Lipidor AB (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor's priority project is AKPO2G2, which focusses on psoriasis.

About AKVANO®

AKVANO® is an innovative water-free and sprayable technology for formulating medicines and is particularly suitable for local application on, for example, the skin. AKVANO® is made up of carefully selected lipids which, together with a volatile solvent, form the carrier of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of active components in the formulation. When applied to the skin, the solvent evaporates and a thin lipid layer is formed on the skin surface for effective release of the active substance.

Attachments

[Lipidor announces that clinical trial material for psoriasis candidate AKPO2G2 has been released according to plan](#)